Axsome Therapeutics, Inc. (AXSM) shares rose 4.6% to $220.75 as of September 12, 2026, a moderate gain from the prior close of $211.12. BestStocks flagged the session as a major change for AXSM. Below, we break down what changed for AXSM, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
What happened
AXSM climbed 4.6% to $220.75
AXSM rose 4.6% in its latest session, moving from $211.12 to $220.75.
ActivityMedium confidence
Rel. volume
1.5×
Normal
Vs peers
—
No comparable peers
Market cap
$11.4B
NASDAQ Global Market
Analyst target
$283
+28.0% vs price
Price chart
Aug 12 – Sep 11
E earnings
F filing
A analyst
V/N other
click a marker to highlight
Change events — click to jump to details
What it means for Axsome Therapeutics, Inc. investors
For Axsome Therapeutics, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 4.6% session move. Weighing against that: Axsome Therapeutics, Inc. (AXSM) moved -2.97% from $237.04 to $230.00 on 2026-07-17; Axsome Therapeutics, Inc. (AXSM) moved -6.09% from $248.95 to $233.80 on 2026-07-10, reaching a new 30-day low. Wall Street's consensus price target sits at $282.53, implying +28.0% upside from $220.75. BestStocks rates the overall signal quality medium (60/100). With earnings roughly 51 days out, the next report is the most likely near-term test of the move.
AXSM price reaction
AXSM last traded at $220.75, up $9.64 (+4.56%) from the previous close of $211.12. The session traded on 1.5× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $198.52 and $220.75, and it currently sits about 100% of the way up that band.
Bullish and bearish analyst opinions on Axsome Therapeutics, Inc. (AXSM)
The consensus analyst price target on Axsome Therapeutics, Inc. (AXSM) is $282.53, 28.0% above the recent $220.75. Over the past 90 days analysts logged 0 upgrades, 12 maintains, and 0 downgrades. Here is how the bullish and bearish cases on AXSM line up.
▲ The bullish case
+Wall Street's consensus price target of $282.53 implies +28.0% upside from $220.75.
+The Street's most bullish target is $380.00 (+72.1%).
+Material positive event.
+Positive 4.6% session move.
+Positive price momentum.
▼ The bearish case
−Axsome Therapeutics, Inc. (AXSM) moved -2.97% from $237.04 to $230.00 on 2026-07-17.
Bull vs bear balanceNeutral / Mixed
BearishNeutralBullish
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 11, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Axsome Therapeutics, Inc. (AXSM) moved +3.35% from $203.11 to $209.92 on 2026-09-02. We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found. Volume remained near its 5-day average at 1.2x.
Axsome Therapeutics (AXSM) declined 2.65% to $200.79 following an August 10 earnings miss—the company reported a Q2 loss of $0.99 per share versus consensus of $0.89, with revenue of $218.4 million also falling short. Wall Street subsequently lowered 2026–2027 earnings estimates, and insider selling of roughly $46.7 million over the past 90 days has added near-term selling pressure, according to multiple analyst notes cited by finance.yahoo.com and marketwatch.com.
Axsome Therapeutics declined 2.17% to $200.94 amid modest profit-taking and technical consolidation, with no material negative catalyst identified. Volume of 287,959 shares is running 0.45x the expected level for this point in the session, suggesting light activity. The pullback follows the company's strong Q2 revenue performance ($218.4M, +46% YoY per Yahoo Finance), which had driven a 16% year-to-date gain.
Axsome Therapeutics fell 5.05% to $207.18 following analyst expectations for a significant earnings decline, per Yahoo Finance. The stock has now experienced a second major drug setback according to MarketWatch reporting. Volume of 338,931 shares traded at 0.52x the time-adjusted average, indicating below-typical activity for this point in the session.
Material / Earnings2026-08-11-2.3%
Axsome Therapeutics, Inc. (AXSM) moved -2.95% on 2026-08-11, one day after the company reported Q2 FY2026 earnings that missed the EPS consensus estimate by 10.98%, with reported EPS of -$0.99 versus the -$0.89 estimate.
Material / Earnings2026-08-10+3.8%
Axsome Therapeutics, Inc. (AXSM) reported Q2 FY2026 EPS of −$0.99 vs. −$0.89 consensus estimate, missing by 11.0% on 2026-08-10.
Filings2026-08-10+3.8%
Axsome Therapeutics, Inc. (AXSM) filed a new 8-K on August 10, 2026. The filing contents were not detailed in available records.
Material / Earnings2026-08-03-3.2%
Axsome Therapeutics, Inc. (AXSM) moved -3.20% from $218.01 to $211.04 on 2026-08-03, reaching a new 30-day low on modestly elevated volume (1.5x the 5-day average). We checked news, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
In-depth AXSM event analyses
Permanent, dated analyses of AXSM's most significant sessions.
Why did Axsome Therapeutics, Inc. (AXSM) stock move?
AXSM rose 4.6% to $220.75. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did AXSM stock rise?
AXSM gained 4.56% ($9.64) versus the prior close of $211.12, last trading at $220.75 on 1.5× average volume.
When is Axsome Therapeutics, Inc.'s next earnings date?
AXSM's next earnings report is estimated for 2026-11-02 — about 51 days away.
What is the analyst price target for AXSM?
The consensus analyst price target for AXSM is $282.53, about 28.0% above the current $220.75. Over the past 90 days, analysts recorded 0 upgrades, 12 maintains, and 0 downgrades.
How BestStocks tracks AXSM
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared AXSM-specific materiality thresholds, triggering an evidence check. It draws on 20 tracked change events for AXSM, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 12, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
